FORT LAUDERDALE, Fla., March 07, 2017 -- Securities Arbitration and Investment Litigation Lawyers with multiple law firms are investigating customer claims against Raymond James, Morgan Stanley and BofA Merrill Lynch (and others) for their recommendations and solicitations of Linn Energy LLC limited liability company interests to retail customers, including in a May 2015 securities offering.
Investors in Linn Energy have been financially devastated by Linn Energy’s bankruptcy filing and may have legal claims to recover their losses as against the brokerage firms that recommended the investment.
The securities arbitration and investment litigation lawyers at the Ciklin Lubitz Law Firm, The Law Firm of David R. Chase, P.A., and Silver Law Group are investigating Raymond James, Morgan Stanley and RBC Capital Markets, among others, as to the suitability and appropriateness of their investment recommendations of Linn Energy to their customers.
If you purchased Linn Energy, or other oil and gas stock, based upon the recommendation of your stock broker or financial advisor, you may contact us to discuss your potential case and legal rights.
For a free and confidential consultation call: 1-800-856-3352
or visit: www.oilgasinvestmentfraudlawyer.com. No recovery, no attorneys’ fees.


Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 



